Advanced Ret Fusion Positive Non Small Cell Lung Cancer — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for advanced ret fusion positive non small cell lung cancer. 56 active patents protecting 1 drugs from 1+ originators. First major cliff: 2037. Daily refresh.

1
Approved drugs
56
Active US patents
60/100
Avg vulnerability
$700M
Annual revenue covered

Originators in Advanced Ret Fusion Positive Non Small Cell Lung Cancer

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Eli Lilly 56 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating advanced ret fusion positive non small cell lung cancer. Each bar = one year. Y-axis scaled to peak year (28 patents).

18
37
28
38
10
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Retevmo
SELPERCATINIB
 Eli Lilly 56 60 $700M 2037-10-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10172851 Retevmo method of use 75 2037-10-10
10172851 Retevmo method of use 75 2037-10-10
10172851 Retevmo method of use 75 2037-10-10
10172851 Retevmo method of use 75 2037-10-10
10137124 Retevmo method of use 75 2037-10-10
10137124 Retevmo method of use 75 2037-10-10
10137124 Retevmo method of use 75 2037-10-10
10137124 Retevmo method of use 75 2037-10-10
12138250 Retevmo method of use 75 2038-10-10
12138250 Retevmo method of use 75 2038-10-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10112942 Retevmo composition of matter 4 2037-10-10
10112942 Retevmo composition of matter 4 2037-10-10
10112942 Retevmo composition of matter 17 2037-10-10
10112942 Retevmo composition of matter 17 2037-10-10
10112942 Retevmo composition of matter 17 2037-10-10
10112942 Retevmo composition of matter 17 2037-10-10
12138250 Retevmo other 62 2039-04-10
12138250 Retevmo other 62 2039-04-10
12138250 Retevmo other 62 2039-04-10
10786489 Retevmo other 62 2039-04-10

Related